Mateos, M., Bahlis, N., Perrot, A., Nooka, A., Lu, J., Pawlyn, C., Mina, R., Caeiro, G., Kentos, A., Hungria, V., Reece, D., Niu, T., Mylin, A., Hansen, C., Teipel, R., Besemer, B., Dimopoulos, M., Zamagni, E., Yoshihara, S., Kim, K., Min, C., Geerts, P., Leeuwen-Segarceanu, E. V., Tyczyńska, A., Reguera, J. L., Johansson, M., Hansson, M., Turgut, M., Grey, M., Sidana, S., Rodriguez-Otero, P., Martínez-López, J., Hashmi, H., Carson, R., Kobos, R., Sun, W., Lantz, K., Seifert, A., Briseno-Toomey, D., O'Rourke, L., Rubin, M., Vieyra, D., Kang, L., Costa, L. (2025). Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3. Blood. https://doi.org/10.1182/blood-2025-lba-6